Miquelianin (Quercetin 3-glucuronide) is a potent stilbene oxidase inhibitor, it has antioxidant, anti-atherogenic, and anti-inflammatory activities.

In vitro studies indicate that miquelianin is able to reach the central nervous system from the small intestine [1]. Miquelianin shows an antioxidant effect in human plasma. At 50 μM, miquelianin suppresses the consumption of the three antioxidants lycopene, β-carotene, and α-tocopherol significantly [2]. Miquelianin significantly reduces the generation of β-amyloid (Aβ) peptides by primary neuron cultures generated from the Tg2576 AD mouse model. It is also capable of interfering with the initial protein-protein interaction of Aβ1–40 and Aβ1–42 [3]. Treatment with 0.1 μM miquelianin suppresses ROS generation, cAMP and RAS activation, phosphorylation of ERK1/2 and the expression of HMOX1, MMP2, and MMP9 genes. Miquelianin suppresses invasion of MDA-MB-231 breast cancer cells and MMP-9 induction and inhibits the binding of [3H]-NA to b2-AR [4].

Miquelianin treatment, compared to vehicle-control treatment, significantly improves AD-type deficits in hippocampal formation basal synaptic transmission and long-term potentiation [3].